Related Experiment Video
Updated: Aug 9, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Gene therapy for ischemic heart disease: therapeutic potential
1Division of Cardiothoracic Surgery, St. Elizabeth's Medical Center of Boston, Tufts University School of Medicine, Boston, Massachusetts, USA. james_symes@cchcs.org
Summary
Gene therapy using vascular endothelial growth factor (VEGF) DNA shows promise for treating cardiovascular diseases by improving blood flow to the heart. Early clinical trials indicate it is well-tolerated and may reduce angina symptoms in patients with severe coronary artery disease.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Regenerative Medicine
Background:
- Gene therapy is emerging as an alternative to traditional treatments for cardiovascular diseases.
- Angiogenic growth factors delivered via gene therapy can improve blood flow to ischemic heart muscle.
- Sustained therapeutic protein expression is a key advantage of gene therapy over recombinant protein administration.
Purpose of the Study:
- To evaluate the efficacy and safety of gene transfer therapy for improving myocardial perfusion.
- To assess the potential of vascular endothelial growth factor (VEGF) gene therapy in patients with coronary artery disease and angina.
- To explore novel delivery methods for angiogenic gene therapy.
Main Methods:
- Utilized adenoviral vectors and naked plasmid DNA for gene delivery.
- Investigated intra-arterial and intramuscular injection routes for DNA delivery to the myocardium.
- Conducted phase I clinical trials involving intramyocardial injection of VEGF DNA, including percutaneous catheter techniques.
Main Results:
- Gene transfer using plasmid DNA demonstrated good tolerability in phase I trials.
- Initial results suggest improvements in myocardial perfusion and reductions in anginal symptoms.
- Percutaneous delivery methods have enabled randomized, placebo-controlled trials.
Conclusions:
- Intramyocardial VEGF gene therapy is a promising approach for myocardial revascularization.
- Further randomized trials are needed to confirm efficacy and optimize delivery vectors and techniques.
- Gene therapy offers a novel therapeutic strategy for patients with inoperable coronary artery disease.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...